

1 **Evaluation of high-throughput SARS-CoV-2 serological assays in**
2 **a longitudinal cohort of mild COVID-19 patients: sensitivity,**
3 **specificity and association with virus neutralization test**

4 Antonin Bal^{1,2}, Bruno Pozzetto^{3,4}, Mary-Anne Trabaud¹, Vanessa Escuret^{1,2}, Muriel
5 Rabilloud^{5,6}, Carole Langlois-Jacques^{5,6}, Adèle Paul^{7,8}, Nicolas Guibert^{7,8}, Constance
6 D'Aubarede^{7,8}, Amélie Massardier-Pilonchery^{7,8}, André Boibieux⁹, Florence Morfin^{1,2},
7 Virginie Pitiot⁸, François Gueyffier^{6,10}, Bruno Lina^{1,2}, Jean-Baptiste Fassier^{7,8}, Sophie
8 Trouillet-Assant² COVID SER STUDY GROUP

9 ¹Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre
10 National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon,
11 France

12 ²CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm,
13 U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon,
14 France

15 ³GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), Université Jean
16 Monnet, Lyon University, Saint-Etienne, France

17 ⁴Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, Saint-
18 Etienne, France

19 ⁵Université de Lyon, F-69000, Lyon, France; Université Lyon 1, F-69100, Villeurbanne,
20 France; Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique et
21 Bioinformatique, F-69003, Lyon, France

22 ⁶CNRS, UMR 5558, University of Lyon, Laboratoire de Biométrie et Biologie Evolutive,
23 Equipe Biostatistique-Santé, 69100, Villeurbanne, France.

24 ⁷Lyon University, Université Claude Bernard Lyon1, Ifsttar, UMRESTTE, UMR T_9405, 8
25 avenue Rockefeller Lyon, France

26 ⁸Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France.

27 ⁹Infectious Diseases Department, Hospices Civils de Lyon, Lyon, France.

28 ¹⁰Pharmacotoxicology Department, Hospices Civils de Lyon, Lyon, France.

29

30 **Corresponding author:** Dr Sophie Trouillet-Assant, Ph.D

31 Hospices Civils de Lyon, France

32 Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm,U1111,
33 Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007, Lyon, France

34 Phone: + 33 (0)472678780 Email: sophie.assant@chu-lyon.fr

35 **Keywords:** COVID-19; SARS-CoV-2; Serological assays; Virus neutralization; Health-care
36 workers

37 **Objectives:** We evaluated widely-used SARS-CoV-2 serological tests and their potential
38 association with virus neutralization test (VNT) in a cohort of mild COVID-19 patients.

39 **Methods:** A total of 439 specimens were longitudinally collected from 76 healthcare workers
40 with RT-PCR-confirmed mild COVID-19. Nine serological assays developed by leading
41 global companies (Abbott, DiaSorin, Siemens, Bio-Rad, Wantai, bioMérieux, Euroimmun)
42 were assessed. For each test the sensitivity to detect SARS-CoV-2 antibodies was determined
43 weekly after symptom onset. Correlation and concordance were assessed using the Spearman
44 and Cohen's Kappa coefficients, respectively. Positive percent agreement and negative
45 percent agreement (NPA) with the VNT were also determined.

46 **Results:** The Wantai Total Ab assay targeting the receptor binding domain (RBD) within the
47 S protein presented the best sensitivity at different times during the course of disease. The
48 best correlation between antibody level and neutralizing antibody titer was found with the
49 Euroimmun S1-based IgA assay (Spearman coefficient [95%CI]: 0.71 [0.61-0.79]). A
50 moderate concordance (Kappa [95%CI]: 0.43[0.23-0.63]) as well as the lowest NPA (33%)
51 was found between the Wantai Total Ab assay and the VNT. Compared to the Wantai Total
52 Ab assay, other total Ab or IgG assays targeting the S or the RBD (bioMérieux, DiaSorin,
53 Siemens,) were more concordant with the VNT (Kappa>0.7 for the three tests) and had a
54 higher NPA (range: 90% to 97%).

55 **Conclusions:** Although some assays presented a better concordance with VNT than others,
56 the present findings emphasize that commercialized serological tests including those targeting
57 the RBD cannot substitute VNT for the assessment of functional antibody response.

58 **Introduction**

59 The evaluation of the humoral immune response to SARS-CoV-2 with serological tests is
60 crucial to further manage the coronavirus disease 2019 (COVID-19) pandemic. Serological
61 testing represents an easy to implement and cost-effective method allowing to rapidly identify
62 individuals exposed to the virus [1,2]. Over the last few months, a large number of SARS-
63 CoV-2 commercial assays have been evaluated for their ability to detect specific antibodies
64 [3–8]. However, the detection of specific SARS-CoV-2 antibodies does not indicate whether
65 or not the antibodies are functional for neutralizing the virus. In association with the
66 evaluation of other immune responses, such as cellular immunity, the determination of
67 neutralizing antibody titer is important to evaluate the protective immunity to SARS-CoV-2
68 after infection and therefore the risk of reinfection [9–11]. While the comparison of sensitivity
69 and specificity of serological tests has been increasingly studied, the association between the
70 results obtained with commercial tests and the virus neutralization test (VNT) has been
71 explored in only a few studies, and mostly among severe COVID-19 patients [12,13]. VNT is
72 considered as the reference to assess the functional ability of antibodies to block the entry of
73 the virus into human cells [14]. However, such an assay requires living virus manipulated in a
74 biosafety level 3 (BSL3) facility that needs trained staff and specific equipment, and which is
75 a tedious and time-consuming method. The first study exploring the association of
76 commercial serological assays and VNT claimed that the Wantai Total Ab assay detecting
77 total antibodies directed against the SARS-CoV-2 receptor binding domain (RBD) had the
78 best characteristics to detect functional antibodies at different stages and severity of disease
79 [12]. The RBD, within the sub-unit S1 of the spike protein, enables the viral entry into human
80 cells by fixing to the angiotensin-converting enzyme 2 (ACE2) receptor [15]. As emphasized
81 by the authors [12], there is an urgent need for further studies addressing the performance of

82 alternative high-throughput assays in correlation with neutralization among persons with mild
83 COVID-19.

84 Thus, the aim of the present study was to evaluate widely-used, high-throughput tests in a
85 longitudinal cohort of mild COVID-19 patients by including the comparison with a VNT.

86 **Methods**

87 **Study design and sample collection**

88 A prospective longitudinal cohort study was conducted at the laboratory associated with the
89 National reference center for respiratory viruses (University Hospital of Lyon, France)[16].
90 Healthcare workers (HCW) with symptoms suggesting a SARS-CoV-2 infection requiring a
91 reverse transcriptase (RT)-PCR test were included. Patients with a positive RT-PCR result at
92 inclusion (V1) returned weekly for 6 additional visits (V2-V7) for serum samples. Written
93 informed consent was obtained from all participants; ethics approval was obtained from the
94 national review board for biomedical research in April 2020 (*Comité de Protection des*
95 *Personnes Sud Méditerranée I*, Marseille, France; ID RCB 2020-A00932-37), and the study
96 was registered on ClinicalTrials.gov (NCT04341142). A total of 439 serum specimens were
97 longitudinally collected from 76 HCW; with the exception of one patient who required
98 hospitalization (not in intensive care unit), all of them developed mild forms of COVID-19.
99 Among the 439 collected samples, 170 of them taken at V2, V4, V7 from 56 patients were
100 tested by VNT.

101 **Virological investigation**

102 COVID-19 diagnosis for inclusion was performed by RT-PCR on nasopharyngeal swab using
103 the cobas® SARS-CoV-2 assay (Roche, Basel, Switzerland).

104 A total of 9 serological assays developed by leading global companies in the field (Abbott,
105 DiaSorin, Siemens, Bio-Rad, Wantai, bioMérieux, Euroimmun) were investigated according
106 to the protocol recommended by each manufacturer (characteristics are summarized in Table
107 1). Positivity was established according to threshold value recommended by each
108 manufacturer. As previously suggested, we also evaluated a cut-off (OD ratio ≥ 10) to
109 indicate the presence of protective antibodies for the Wantai Total Ab assay [12].

110 The VNT used for the detection and titration of neutralizing antibodies was performed as
111 previously described [17]. Briefly, a ten-fold dilution of each serum specimen in culture
112 medium (Dulbecco's Modified Eagle Medium containing antibiotics and 2% foetal calf
113 serum) was first heated for 30 min at 56°C to avoid complement-linked reduction of the viral
114 activity. Serial two-fold dilutions (tested in duplicate) of the serum specimens in culture
115 medium were mixed at equal volume with the live SARS-CoV2 virus. After gentle shaking
116 and a contact of 30 minutes at room temperature in plastic microplates, 150 μ L of the mix was
117 transferred into 96-well microplates covered with Vero E6 cells. The plates were incubated at
118 37°C in a 5% CO₂ atmosphere. The reading was evaluated microscopically 5 to 6 days later
119 when the cytopathic effect of the virus control reached 100 TCID₅₀/150 μ L. Neutralization
120 was recorded if more than 50% of the cells present in the well were preserved. The
121 neutralizing titer was expressed as the inverse of the higher serum dilution that exhibited
122 neutralizing activity; a threshold of 20 was used. All experiments were performed in a BSL3
123 laboratory. The comparison of this VNT with a standardized assay using retroviruses pseudo-
124 typed with the SARS-CoV-2 S viral surface protein found a high correlation and concordance
125 [17].

126 **Statistical analyses**

127 For each test the clinical sensitivity was determined weekly after symptom onset. The
128 correlation and concordance with the VNT were assessed using the Spearman and Cohen's
129 Kappa coefficients, respectively. The concordance was classified as slight (Cohen's Kappa
130 coefficient, [0-0.2]), fair [0.21-0.4], moderate [0.41-0.6], substantial [0.61-0.8], and almost
131 perfect [0.81-1] according to Landis and Koch criteria. The positive and negative percentage
132 agreements (PPA, NPA) were also determined. The estimation of the correlation coefficient
133 was not performed due to an upper limit of signal to cut-off ratio for the Siemens and Bio-Rad
134 assays. Specificity was assessed with 30 pre-pandemic serum specimens collected from
135 healthy donors in 2019. The estimates are given with their bilateral 95% confidence interval
136 (CI) calculated using the Wilson method. The 95% CI for Cohen's Kappa coefficient was
137 calculated using the bootstrap percentile method. The paired comparison of sensitivity
138 between two assays was performed with the non-parametric McNemar test. A p-value < 0.05
139 was considered as statistical significant.

140 **Results**

141 **Sensitivity and specificity**

142 During the first week after the onset of symptoms the sensitivity for the detection of
143 antibodies ranged from 6.6% (DiaSorin, Liaison) to 25.0% (Euroimmun). The second week
144 the sensitivity was greater than 70% for three tests including Bio-Rad, Wantai Total Ab, and
145 Euroimmun IgA assays (74.2%, 79.0% and 72.6%, respectively). The highest of sensitivity
146 was found at week # 3 for Bio-Rad (96.6%), Wantai Total Ab (100%), Wantai IgM (94.9%),
147 bioMérieux IgM (78.0%) and Euroimmun (96.6%), at week # 4 for Abbott (93.2%), and at
148 week # 6 for Diasorin (93.2%), Siemens (98.3%) and bioMérieux IgG (94.9%). After this
149 point, a decrease of sensitivity was noted for all assays except for the Wantai Total Ab which
150 remained steady at 100% over the course of the disease (Table 1). Compared to the Wantai
151 Total Ab assay, the differences were significant before 14 days post-symptom onset with all
152 other assays, except with the Euroimmun and Bio-Rad assays; after 14 days post-symptom
153 onset, the differences were significant with all other assays.

154 Regarding specificity, no false positive result was found using 30 pre-pandemic sera, although
155 3 samples gave a borderline ratio (between 0.8 and 1.1) with the Euroimmun IgA assay
156 (supplementary table 1).

Manufacturer (platform)	Abbott (Architect)	DiaSorin (Liaison®)	Siemens (Atellica®)	Bio-Rad	Wantai		bioMérieux (Vidas®)		Euroimmun
Assay name	SARS-CoV-2 IgG	SARS-CoV-2 S1/S2 IgG	SARS-CoV-2 Total	Platelia SARS-CoV-2 Total Ab	SARS-CoV-2 Total Ab	SARS-CoV-2 IgM	SARS-CoV-2 IgG	SARS-CoV-2 IgM	SARS-CoV-2 IgA
Assay type	CMIA	CLIA	CLIA	ELISA	ELISA	ELISA	ELFA	ELFA	ELISA
Antigen	N	S1+S2	RBD	N	RBD	RBD	RBD	RBD	S1

Sensitivity vs SARS-CoV2 RT-PCR [95%CI]

days after symptom onset (n)	Abbott (Architect)	DiaSorin (Liaison®)	Siemens (Atellica®)	Bio-Rad	Wantai (SARS-CoV-2 Total Ab)	Wantai (SARS-CoV-2 IgM)	bioMérieux (Vidas®) (SARS-CoV-2 IgG)	bioMérieux (Vidas®) (SARS-CoV-2 IgM)	Euroimmun (SARS-CoV-2 IgA)
[1-7] (61)	9.84 [5.17-17.91]	6.56 [2.98-13.83]	6.56 [2.98-13.83]	18.03 [11.35-27.43]	22.95 [15.36-32.84]	13.11 [7.55-21.81]	8.20 [4.05-15.90]	11.48 [6.34-19.88]	25.00 [17.02-36.44]
[8-14] (63)	59.68 [49.23-69.31]	32.26 [23.41-42.59]	41.94 [32.18-52.37]	74.19 [64.18-82.19]	79.03 [69.41-86.23]	64.52 [54.11-73.71]	39.68 [30.17-50.04]	49.21 [39.09-59.38]	72.58 [62.47-80.81]
[15-21] (59)	91.53 [83.60-95.81]	83.05 [73.61-89.59]	89.83 [81.52-94.65]	96.61 [90.26-98.87]	100.00 [95.62-100.00]	94.92 [87.94-97.95]	86.44 [77.50-92.19]	77.97 [67.97-85.50]	96.61 [90.26-98.87]
[22-28] (59)	93.22 [85.73-96.92]	86.44 [77.50-92.19]	93.22 [85.73-96.92]	94.92 [87.94-97.95]	100.00 [95.62-100.00]	89.83 [81.52-94.65]	93.22 [85.73-96.92]	69.49 [58.96-78.32]	91.53 [83.60-95.81]
[29-35] (65)	86.15 [77.66-91.76]	92.31 [85.03-96.21]	93.85 [86.98-97.21]	92.19 [84.81-96.15]	100.00 [96.00-100.00]	84.62 [75.89-90.58]	90.77 [83.13-95.15]	52.31 [42.23-62.20]	84.62 [75.89-90.58]
[36-42] (59)	89.83 [81.52-94.65]	93.22 [85.73-96.92]	98.31 [92.75-99.62]	91.53 [83.60-95.81]	100.00 [95.62-100.00]	88.14 [79.49-93.44]	94.92 [87.94-97.95]	45.76 [35.51-56.38]	88.14 [79.49-93.44]
[43-85] (73)	89.04 [81.58-93.71]	89.04 [81.58-93.71]	95.89 [90.15-98.35]	88.89 [81.34-93.62]	100.00 [96.38-100.00]	81.94 [73.38-88.20]	87.67 [79.97-92.68]	43.84 [34.67-53.44]	79.45 [70.69-86.81]

159 Table 1 – Sensitivity of the serological assays was determined by comparing the outcome to positive SARS-CoV-2 PCR. Positivity was
160 established according to threshold value recommended by each manufacturer. Ab: antibodies, Ig: immunoglobulin, ELISA: enzyme-linked
161 immunosorbent assay, CMIA: chemiluminescence microparticle immune assay CLIA: chemiluminescence immune assay, ELFA: enzyme-
162 linked fluorescent assay, n: number of samples, CI: confidence interval.

163 **Kinetics of neutralizing antibody titers**

164 The neutralizing capacity of antibodies was determined at three time points for 56 patients
165 (n=170 samples). No neutralizing antibody was detected in 42.0% (21/50), 5.8% (3/51), and
166 8.7% (6/69) of samples collected between, respectively, 1-14, 15-28, and more than 28 days
167 after symptom onset. For the samples with a detection of neutralizing antibody, the median
168 [IQR] titer was 60[40-100] between 1-14 days post symptom, reached 80[60-120] between
169 15-28 days post symptom and decreased in samples collected after more than 28 days
170 (median: 60[40-120]).

171 **Comparison of results between commercial kits and VNT**

172 The best correlation between commercial kits and VNA was found with the Euroimmun S1-
173 based IgA assay (Spearman coefficient [95%CI]: 0.71 [0.61-0.79]) while the Abbott N-based
174 assay presented the lowest correlation (0.46 [0.32-0.59]; Figure 1, Table 2).

175 A slight and fair concordance with VNT were noticed for the 2 IgM assays evaluated herein
176 (Kappa [95%CI]: 0.24 [0.14-0.36] for bioMérieux IgM and 0.40 [0.21-0.58] for the Wantai
177 IgM assays). Regarding total Ab or IgG assays targeting the S protein, three had substantial
178 concordance with VNT (Kappa [95%CI]: 0.71 for bioMérieux [0.57-0.84], 0.70 [0.56-0.83]
179 for DiaSorin, and 0.72 [0.55-0.85] for Siemens assays) while the concordance with the
180 Wantai Total Ab assay was moderate (0.43[0.23-0.63]; Table 2).

181 For the Wantai Total Ab assay, 20/30 samples with no neutralizing antibody had a positive
182 Wantai Total Ab; 18 these had an OD ratio < 10. Of note, 9/30 samples were collected more
183 than 14 days post symptom onset. Regarding the samples with an OD ratio < 10 with the
184 Wantai Total ab assay (39/140, 28%), all had a low level of neutralizing antibodies (range:
185 20-50; Figure 1).

186 The NPA ranged from 33.3% [21.1-48.3] for the Wantai Total Ab assay to 96.8% for the
187 DiaSorin and was < 90% for 7/9 assays. The PPA was > 90% for all tests except the DiaSorin
188 and the two IgM based assays (Wantai and bioMérieux) (Table 2).

Manufacturer (platform)	Abbott (Architect)	DiaSorin (Liaison®)	Siemens (Atellica®)	Bio-Rad	Wantai		bioMérieux (Vidas®)		Euroimmun
Assay name	SARS-CoV-2 IgG	SARS-CoV-2 S1/S2 IgG	SARS-CoV-2 Total	Platelia SARS-CoV-2 Total Ab	SARS-CoV-2 Total Ab	SARS-CoV-2 IgM	SARS-CoV-2 IgG	SARS-CoV-2 IgM	SARS-CoV-2 IgA
Assay type	CMIA	CLIA	CLIA	ELISA	ELISA	ELISA	ELFA	ELFA	ELISA
Antigen	N	S1+S2	RBD	N	RBD	RBD	RBD	RBD	S1
Concordance with virus VNT - Cohen's Kappa coefficient [95%CI]									
Overall (n=170)	0.64 [0.49-0.79]	0.70 [0.56-0.83]	0.72 [0.55-0.85]	0.62 [0.44-0.76]	0.43 [0.23-0.63]	0.40 [0.21-0.58]	0.71 [0.57-0.84]	0.24 [0.14-0.36]	0.61 [0.43-0.76]
<14 dps	0.70 [0.45-0.88]	0.41 [0.19-0.60]	0.68 [0.45-0.84]	0.69 [0.45-0.86]	0.46 [0.21-0.67]	0.61 [0.35-0.79]	0.41 [0.29-0.76]	0.52 [0.27-0.72]	0.60 [0.35-0.79]
>14 dps	0.40 [-0.06-0.72]	0.86 [0.65-1]	0.51 [0-0.89]	0.45 [-0.05-0.79]	NA	0.08 [-0.09-0.35]	0.90 [0.71-1.00]	0.18 [0.02-0.25]	0.55 [0.06-0.81]
Correlation between Ab level and neutralizing Ab titer									
Spearman coefficient [95%CI]	0.46 [0.32-0.59]	0.52 [0.38-0.64]	NA	NA	0.56 [0.43-0.66]	0.52 [0.38-0.64]	0.60 [0.48-0.71]	0.50 [0.31-0.65]	0.71 [0.61-0.79]
Negative and Positive Percent Agreement with VNT									
NPA[95%CI]	74.2 [59.7-84.8]	96.8 [86.8-99.3]	80.7 [66.7-89.7]	61.3 [46.6-74.2]	33.3 [21.1-48.3]	56.7 [41.9-70.4]	90.3 [78.1-96.1]	83.9 [70.4-91.9]	67.7 [53.0-79.6]
PPA[95%CI]	92.1 [87.6-95.1]	87.9 [82.6-91.7]	93.6 [89.3-96.2]	95.7 [91.9-97.8]	99.3 [96.9-99.9]	86.4 [81.0-90.5]	90.1 [85.1-93.5]	57.4 [50.5-64.1]	92.9 [88.4-95.7]

189

190 Table 2 – Comparison between serological assays and virus neutralization test. Ab: antibodies, Ig: immunoglobulin, ELISA: enzyme-linked
 191 immunosorbent assay, CMIA: chemiluminescence microparticle immune assay CLIA: chemiluminescence immune assay, ELFA: enzyme-
 192 linked fluorescent assay, n: number of samples, CI: confidence interval, dps: days post onset of symptoms, test. VNT: Virus neutralization test.
 193 The estimation of the correlation coefficient was not performed due to an upper limit of signal to cut-off ratio for the Siemens and Bio-Rad
 194 assays. The Cohen's Kappa coefficient after 14 days post symptom onset cannot be interpreted for the Wantai Total Ab assay because the
 195 sensitivity of this test was 100%.

196 **Discussion**

197 In a longitudinal study of 76 HCW with RT-PCR-confirmed COVID-19, we found that the
198 Wantai Total Ab assay had the best sensitivity over the course of the disease. In particular, the
199 sensitivity reached and remained at 100% as soon as week # 3 post symptom onset. This
200 finding observed in mild COVID-19 patients is consistent with previous reports of excellent
201 sensitivity of this test notably in severe patients [3,12].

202 In addition to sensitivity, the ability of a commercial test to evaluate the protective immunity
203 needs to be assessed. With this aim, Tang et al. compared three commercial assays (Roche
204 Total Ab, Abbott IgG, both tests targeting the N protein, and Euroimmun IgG assays targeting
205 the S protein) to VNT on 67 specimens [13]. The NPA of these tests was poor, ranging from
206 56% for Roche to 81% for Euroimmun, making them imperfect proxies for neutralization.
207 These findings are highly consistent with those of the present study that found a NPA below
208 90% for all tests except for bioMérieux IgG and DiaSorin. In contrast, it is interesting to note
209 that the Wantai Total Ab had the lowest NPA (33%). Furthermore, the concordance between
210 VNT and the Wantai Total Ab assay was only moderate while the concordance was
211 substantial with bioMérieux IgG, DiaSorin, Siemens, Abbott, Euroimmun and Bio-Rad. The
212 low NPA and moderate concordance noticed for the Wantai Total Ab might be partially
213 explained by the excellent ability of this test to detect RBD-specific antibodies at the very
214 early phase of infection, irrespective of their neutralizing properties in line with the delay
215 required for antibody maturation [18]. In the first study comparing VNT with commercialized
216 tests, the authors found that the Wantai Total Ab assay had the best characteristics to detect
217 functional antibodies in different stages and severity of disease [12]. However the median
218 interval between the onset of symptoms and sample collection was 43 days for mild patients
219 (n=71 samples) and thus the antibodies could be detected with both the Wantai Total Ab and

220 the VNT assay at this time. As the authors used VNT as the gold-standard for sensitivity
221 assessment, this explains the difference in findings with the present study [12].

222 Importantly, as previously reported by others [18,19], not all RBD-binding antibodies have
223 neutralizing properties which is consistent with that reported herein regarding the RBD-based
224 assays that do not have perfect concordance with VNT. Conversely, serological assays
225 targeting a region other than the S protein may be associated with functional information, as
226 previously reported [14,20–22]. In the present study, the Abbott and Bio-Rad assays directed
227 against the N protein presented a substantial concordance with VNT as N-directed and RBD-
228 neutralizing antibodies can be produced concomitantly over the course of the disease.

229 In addition to the different targeted antigens, the heterogeneity in assay performance found
230 herein could also be explained by various factors including the detected isotypes. Moreover,
231 antibody levels may also be very different according to the time since symptom onset and
232 according to clinical severity of the disease [23]. Herein, serum samples were collected
233 longitudinally from disease diagnosis enabling to explore the early phase of the antibody
234 response in a cohort of HCW with mild symptoms, which constitutes one of the main strength
235 of the present study.

236 The present study does, however, have certain limitations. For instance, specificity was not
237 been extensively studied; yet the Euroimmun IgA assay seemed to have the worst specificity,
238 which is consistent with previous studies reporting a lack of specificity for this assay [5,6,12].
239 In addition, the performance of other notable commercial assays such as Euroimmun IgG or
240 Roche Ig Total were not assessed. Second, not all the samples were systematically tested by
241 VNT, in-line with the labor-intensive nature of this method. Finally, the size of the tested
242 population remains small, which limits the extrapolation of the results, although the present
243 study represents the largest one comparing VNT to other serological tests through a
244 longitudinal design.

245 The results presented herein obtained from mild COVID-19 patients confirm that, for
246 exposure assessment, the Wantai Total Ab assay should be preferred to other commercial kits
247 due to a very high sensitivity. For evaluating protective immunity, the Wantai Total Ab assay
248 with an optimized cut-off or other tests targeting the S protein as Euroimmun, DiaSorin or
249 bioMérieux IgG could be more useful, notably to screen serum specimens candidate for the
250 presence of neutralizing antibodies. However, these tests or others cannot substitute a VNT
251 for assessing functional antibody response; neutralizing assays remain the gold standard and
252 easy-to-use tests, such as those based on pseudoviruses [6,17,24], should be developed and
253 standardized. Furthermore, the recent development of surrogate virus neutralization tests
254 based on antibody-mediated blockage of the interaction between ACE-2 receptor and the
255 RBD is very promising as they were designed in an ELISA format enabling high-throughput
256 testing [19,25].

257 In conclusion, the present study provides original data concerning the performance of widely-
258 used serological tests, which could help diagnostic laboratories in the choice of a particular
259 assay according to the intended use.

260 **Figure 1 legend**

261 Correlation of SARS-CoV-2 neutralizing antibody titers tested by a virus neutralization test to
262 antibodies level measured by selected assays. (A) bioMérieux IgM (B) Wantai IgM (C)
263 Euroimmun IgA (D) Wantai total Ab (E) bioMérieux IgG (F) Abbott (G) DiaSorin IgG.
264 Magenta dots indicate patient specimen collected ≤ 14 days post onset of symptoms (dps),
265 orange dots indicate samples collected from 14-28 dps, green dots indicate specimen collected
266 more than 28 dps. Dotted lines indicate the cut-off for positivity of each assay, as indicated by
267 the manufacturer: Wantai, Abbott, bioMérieux, Euroimmun, OD ratio > 1 ; DiaSorin > 12
268 AU/ml. OD: optical density.

269 **COVID-SER study group**

270 Adnot Jérôme, Alfaiate Dulce, Bal Antonin, Bergeret Alain, Boibieux André, Bonnet Florent,
271 Bourgeois Gaëlle, Brunel-Dalmas Florence, Caire Eurydice, Charbotel Barbara, Chiarello
272 Pierre, Cotte Laurent, d'Aubarede Constance, Durupt François, Escuret Vanessa, Fascia
273 Pascal, Fassier Jean-Baptiste, Fontaine Juliette, Gaillot-Durand Lucie, Gaymard Alexandre,
274 Gillet Myriam, Godinot Matthieu, Gueyffier François, Guibert Nicolas, Josset Laurence,
275 Lahousse Matthieu, Lina Bruno, Lozano Hélène, Makhloufi Djamila, Massardier-Pilonchéry
276 Amélie, Milon Marie-Paule, Moll Frédéric, Morfin Florence, Narbey David, Nazare Julie-
277 Anne, Oria Fatima, Paul Adèle, Perry Marielle, Pitiot Virginie, Prudent Mélanie, Rabilloud
278 Muriel, Samperiz Audrey, Schlienger Isabelle, Simon Chantal, Trabaud Mary-Anne,
279 Trouillet-Assant Sophie

280 **Acknowledgements**

281 We thank all the personnel of the occupational health and medicine department of Hospices
282 Civils de Lyon who contributed to the samples collection. We thank Lucie Charreton and
283 Khadija Sfouli for their excellent work concerning serological testing, all the technicians from
284 the virology laboratory whose work made it possible to obtain all these data, as well as Amira

285 Lachekhab and Naima Rolnin for their technical assistance. We thank Karima Brahima and
286 all members of the clinical research and innovation department for their reactivity (DRCI,
287 Hospices Civils de Lyon). We thank Philip Robinson (DRCI, Hospices Civils de Lyon) for
288 his help in manuscript preparation.

289 **Author contributor's statement**

290 All authors were involved in the analysis and interpretation of data as well as drafting the
291 manuscript or revising it critically for important intellectual content. AB, BP, VP, FG, JBF
292 and STA made substantial contributions to the conception and design of the study and
293 designed the experiments. BP performed VNT. MAT and VE performed the serological assay
294 experiments. NG, AP, CA, AMP, AB, and JBF were involved in patient care, VP performed
295 the data collection, STA, AB, MA and BP performed the data analysis. MR and CLJ
296 performed the statistical analysis. AB and STA wrote the paper, BL, BP, JBF, AP, VE and
297 MAT revised the manuscript content. All authors read and approved the final manuscript.

298 **Conflict interests statement**

299 Antonin Bal has received grant from bioMérieux and has served as consultant for bioMérieux
300 for work and research not related to this manuscript. Sophie Trouillet-Assant has received
301 research grant from bioMérieux concerning previous works not related to this manuscript.
302 The other authors have no relevant affiliations or financial involvement with any organization
303 or entity with a financial interest in or financial conflict with the subject matter or materials
304 discussed in the manuscript.

305 **Funding**

306 This research is being supported by Hospices Civils de Lyon and by Fondation des Hospices
307 Civils de Lyon.


308 References

- 309 [1] Krammer F, Simon V. Serology assays to manage COVID-19. *Science* 2020;368:1060–
310 1. <https://doi.org/10.1126/science.abc1227>.
- 311 [2] Winter AK, Hegde ST. The important role of serology for COVID-19 control. *Lancet*
312 *Infect Dis* 2020;20:758–9. [https://doi.org/10.1016/S1473-3099\(20\)30322-4](https://doi.org/10.1016/S1473-3099(20)30322-4).
- 313 [3] Trabaud M-A, Icard V, Milon M-P, Bal A, Lina B, Escuret V. Comparison of eight
314 commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG
315 or total antibody. *J Clin Virol* 2020;132:104613.
316 <https://doi.org/10.1016/j.jcv.2020.104613>.
- 317 [4] Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E,
318 Vandecandelaere P, et al. Antibody response against SARS-CoV-2 spike protein and
319 nucleoprotein evaluated by 4 automated immunoassays and 3 ELISAs. *Clin Microbiol*
320 *Infect* 2020. <https://doi.org/10.1016/j.cmi.2020.07.038>.
- 321 [5] Van Elslande J, Houben E, Depypere M, Brackenier A, Desmet S, André E, et al.
322 Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun
323 IgA/IgG ELISA in COVID-19 patients. *Clin Microbiol Infect* 2020;26:1082–7.
324 <https://doi.org/10.1016/j.cmi.2020.05.023>.
- 325 [6] Meyer B, Torriani G, Yerly S, Mazza L, Calame A, Arm-Vernez I, et al. Validation of a
326 commercially available SARS-CoV-2 serological immunoassay. *Clin Microbiol Infect*
327 2020. <https://doi.org/10.1016/j.cmi.2020.06.024>.
- 328 [7] Theel ES, Haring J, Hilgart H, Granger D. Performance Characteristics of Four High-
329 Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. *J*
330 *Clin Microbiol* 2020;58. <https://doi.org/10.1128/JCM.01243-20>.
- 331 [8] Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui L-P, Johnston JC, et al.
332 Diagnostic accuracy of serological tests for covid-19: systematic review and meta-
333 analysis. *BMJ* 2020;370:m2516. <https://doi.org/10.1136/bmj.m2516>.
- 334 [9] Addetia A, Crawford KH, Dingens A, Zhu H, Roychoudhury P, Huang M, et al.
335 Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a
336 fishery vessel outbreak with high attack rate. *MedRxiv* 2020:2020.08.13.20173161.
337 <https://doi.org/10.1101/2020.08.13.20173161>.
- 338 [10] Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function,
339 durability, and role in protection. *Sci Immunol* 2020;5.
340 <https://doi.org/10.1126/sciimmunol.abd6160>.
- 341 [11] Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et
342 al. A systematic review of antibody mediated immunity to coronaviruses: kinetics,
343 correlates of protection, and association with severity. *Nat Commun* 2020;11:4704.
344 <https://doi.org/10.1038/s41467-020-18450-4>.
- 345 [12] GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et
346 al. An evaluation of COVID-19 serological assays informs future diagnostics and
347 exposure assessment. *Nat Commun* 2020;11:3436. <https://doi.org/10.1038/s41467-020-17317-y>.
- 349 [13] Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, et al.
350 Association between SARS-CoV-2 neutralizing antibodies and commercial serological
351 assays. *Clin Chem* 2020. <https://doi.org/10.1093/clinchem/hvaa211>.
- 352 [14] Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other
353 Human Coronaviruses. *Trends Immunol* 2020;41:355–9.
354 <https://doi.org/10.1016/j.it.2020.03.007>.


- 355 [15] Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
356 associated with a new coronavirus of probable bat origin. *Nature* 2020;579:270–3.
357 <https://doi.org/10.1038/s41586-020-2012-7>.
- 358 [16] Trouillet-Assant et al. Assessment of Serological Techniques for Screening Patients
359 Regarding COVID-19 (COVID-SER): a prospective multicentric study. *BMJ open*.
360 2020. In press., n.d.
- 361 [17] Legros V, Denolly S, Vogrig M, Boson B, Rigai J, Pillet S, et al. A longitudinal study
362 of SARS-CoV-2 infected patients shows high correlation between neutralizing
363 antibodies and COVID-19 severity. *MedRxiv* 2020:2020.08.27.20182493.
364 <https://doi.org/10.1101/2020.08.27.20182493>.
- 365 [18] Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited
366 by SARS-CoV-2 infection. *Nature* 2020;584:115–9. <https://doi.org/10.1038/s41586-020-2380-z>.
- 368 [19] Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, et al. A SARS-CoV-2 surrogate
369 virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-
370 protein interaction. *Nat Biotechnol* 2020;38:1073–8. <https://doi.org/10.1038/s41587-020-0631-z>.
- 372 [20] Tong P-B-V, Lin L-Y, Tran TH. Coronaviruses pandemics: Can neutralizing antibodies
373 help? *Life Sci* 2020;255:117836. <https://doi.org/10.1016/j.lfs.2020.117836>.
- 374 [21] Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2.
375 *Antib Ther* 2020;3:109–14. <https://doi.org/10.1093/abt/tbaa009>.
- 376 [22] Cohen SA, Kellogg C, Equils O. Neutralizing and cross-reacting antibodies:
377 implications for immunotherapy and SARS-CoV-2 vaccine development. *Hum Vaccin*
378 *Immunother* 2020:1–4. <https://doi.org/10.1080/21645515.2020.1787074>.
- 379 [23] Rijkers G, Murk J-L, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al.
380 Differences in antibody kinetics and functionality between severe and mild SARS-CoV-
381 2 infections. *J Infect Dis* 2020. <https://doi.org/10.1093/infdis/jiaa463>.
- 382 [24] Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Establishment and validation of a
383 pseudovirus neutralization assay for SARS-CoV-2. *Emerg Microbes Infect* 2020;9:680–
384 6. <https://doi.org/10.1080/22221751.2020.1743767>.
- 385 [25] Byrnes JR, Zhou XX, Lui I, Elledge SK, Glasgow JE, Lim SA, et al. A SARS-CoV-2
386 serological assay to determine the presence of blocking antibodies that compete for
387 human ACE2 binding. *MedRxiv* 2020. <https://doi.org/10.1101/2020.05.27.20114652>.
- 388

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).


A




B




C




D



E



F



G

